ND
Therapeutic Areas
Unity Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| UBX1325 (foselutoclax) | Diabetic Macular Edema (DME) | Phase 2b |
| UBX0105 | Moderate-to-Severe Osteoarthritis of the Knee | Phase 2 |
| UBX1967 | Diabetic Macular Edema (DME), Wet AMD | Phase 1 |
Leadership Team at Unity Biotechnology
AG
Anirvan Ghosh, Ph.D.
Former Chief Executive Officer
KR
Keith R. Leonard, Jr.
Former Chairman of the Board
ND
Nathaniel David, Ph.D.
Co-founder, Former President
JD
Jamie Dananberg, M.D.
Former Chief Medical Officer
LR
Leah R. Mische, J.D.
Former General Counsel